• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.

作者信息

Subbiah V, Solit D B, Chan T A, Kurzrock R

机构信息

Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program), Division of Cancer Medicine, UT MD Anderson Cancer Center, Houston, USA.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Marie-Josée and Henry R. Kravis Center for Molecular Oncology, Memorial Sloan Kettering Cancer Center, New York, USA.

出版信息

Ann Oncol. 2020 Sep;31(9):1115-1118. doi: 10.1016/j.annonc.2020.07.002. Epub 2020 Aug 5.

DOI:10.1016/j.annonc.2020.07.002
PMID:32771306
Abstract
摘要

相似文献

1
The FDA approval of pembrolizumab for adult and pediatric patients with tumor mutational burden (TMB) ≥10: a decision centered on empowering patients and their physicians.美国食品药品监督管理局（FDA）批准帕博利珠单抗用于肿瘤突变负荷（TMB）≥10的成人和儿童患者：一项以赋予患者及其医生权力为核心的决定。
Ann Oncol. 2020 Sep;31(9):1115-1118. doi: 10.1016/j.annonc.2020.07.002. Epub 2020 Aug 5.
2
The FDA approval of pembrolizumab for patients with TMB >10 mut/Mb: was it a wise decision? No.美国食品药品监督管理局（FDA）批准帕博利珠单抗用于肿瘤突变负荷（TMB）>10个突变/Mb的患者：这是一个明智的决定吗？不是。
Ann Oncol. 2020 Sep;31(9):1112-1114. doi: 10.1016/j.annonc.2020.07.001. Epub 2020 Aug 5.
3
FDA Approval Summary: Pembrolizumab for the Treatment of Tumor Mutational Burden-High Solid Tumors.FDA 批准概要：帕博利珠单抗治疗肿瘤突变负担高的实体瘤。
Clin Cancer Res. 2021 Sep 1;27(17):4685-4689. doi: 10.1158/1078-0432.CCR-21-0327. Epub 2021 Jun 3.
4
Tumor Mutational Burden as a Pan-cancer Biomarker for Immunotherapy: The Limits and Potential for Convergence.肿瘤突变负荷作为一种泛癌种免疫治疗生物标志物：局限性和趋同的潜力。
Cancer Cell. 2020 Nov 9;38(5):624-625. doi: 10.1016/j.ccell.2020.10.019.
5
T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028.T 细胞炎症基因表达谱、程序性死亡配体 1 表达和肿瘤突变负担可预测帕博利珠单抗治疗 20 种癌症患者的疗效：KEYNOTE-028。
J Clin Oncol. 2019 Feb 1;37(4):318-327. doi: 10.1200/JCO.2018.78.2276. Epub 2018 Dec 13.
6
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study.帕博利珠单抗治疗的晚期实体瘤患者肿瘤突变负荷与结局的相关性：多队列、开放标签、Ⅱ期 KEYNOTE-158 研究的前瞻性生物标志物分析。
Lancet Oncol. 2020 Oct;21(10):1353-1365. doi: 10.1016/S1470-2045(20)30445-9. Epub 2020 Sep 10.
7
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗微卫星高度不稳定实体瘤。
Clin Cancer Res. 2019 Jul 1;25(13):3753-3758. doi: 10.1158/1078-0432.CCR-18-4070. Epub 2019 Feb 20.
8
First Tissue-Agnostic Drug Approval Issued.首个组织非特异性药物获批。
Cancer Discov. 2017 Jul;7(7):656. doi: 10.1158/2159-8290.CD-NB2017-078. Epub 2017 Jun 5.
9
Significance and implications of FDA approval of pembrolizumab for biomarker-defined disease.FDA 批准帕博利珠单抗用于生物标志物定义的疾病的意义和影响。
J Immunother Cancer. 2018 May 14;6(1):35. doi: 10.1186/s40425-018-0342-x.
10
FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.美国食品药品监督管理局批准摘要：帕博利珠单抗用于治疗肿瘤表达程序性死亡配体1的转移性非小细胞肺癌患者。
Oncologist. 2016 May;21(5):643-50. doi: 10.1634/theoncologist.2015-0498. Epub 2016 Mar 29.

引用本文的文献

1
Clinical and Molecular Differences Suggest Different Responses to Immune Checkpoint Inhibitors in Microsatellite-Stable Solid Tumors with High Tumor Mutational Burden.临床和分子差异表明，微卫星稳定的实体瘤且肿瘤突变负荷高的患者对免疫检查点抑制剂有不同反应。
Cancers (Basel). 2025 Aug 16;17(16):2673. doi: 10.3390/cancers17162673.
2
Clinical efficacy of immune checkpoint inhibitors for cancer of unknown primary: a multi-center retrospective study.免疫检查点抑制剂治疗原发灶不明癌症的临床疗效：一项多中心回顾性研究
BMC Cancer. 2025 Aug 16;25(1):1323. doi: 10.1186/s12885-025-14778-6.
3
Emerging Concepts in Immuno-Oncology: Insights from Natural Language Processing-Driven Co-Occurrence Analysis.
免疫肿瘤学中的新兴概念：来自自然语言处理驱动的共现分析的见解
ACS Omega. 2025 Jun 27;10(27):28587-28614. doi: 10.1021/acsomega.5c00693. eCollection 2025 Jul 15.
4
Tissue-agnostic cancer therapies: promise, reality, and the path forward.组织非特异性癌症疗法：前景、现状与未来之路。
Nat Commun. 2025 May 29;16(1):4972. doi: 10.1038/s41467-025-60369-1.
5
Immunotherapy in breast cancer: current landscape and emerging trends.乳腺癌的免疫治疗：现状与新趋势
Exp Hematol Oncol. 2025 May 22;14(1):77. doi: 10.1186/s40164-025-00667-y.
6
Next-Generation Sequencing in Oncology-A Guiding Compass for Targeted Therapy and Emerging Applications.肿瘤学中的下一代测序——靶向治疗及新兴应用的指南
Int J Mol Sci. 2025 Mar 28;26(7):3123. doi: 10.3390/ijms26073123.
7
Progress of PD-1/PD-L1 immune checkpoint inhibitors in the treatment of triple-negative breast cancer.PD-1/PD-L1免疫检查点抑制剂在三阴性乳腺癌治疗中的进展
Cancer Cell Int. 2025 Apr 10;25(1):139. doi: 10.1186/s12935-025-03769-z.
8
A redefined InDel taxonomy provides insights into mutational signatures.重新定义的插入缺失分类法为突变特征提供了见解。
Nat Genet. 2025 May;57(5):1132-1141. doi: 10.1038/s41588-025-02152-y. Epub 2025 Apr 10.
9
Pretrained transformers applied to clinical studies improve predictions of treatment efficacy and associated biomarkers.应用于临床研究的预训练变压器可改善对治疗效果及相关生物标志物的预测。
Nat Commun. 2025 Mar 1;16(1):2101. doi: 10.1038/s41467-025-57181-2.
10
Recent progress in emerging molecular targeted therapies for intrahepatic cholangiocarcinoma.肝内胆管癌新兴分子靶向治疗的最新进展
RSC Med Chem. 2025 Feb 6. doi: 10.1039/d4md00881b.